Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study

@article{Sanches2016AntidepressantEO,
  title={Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study},
  author={Rafael F Sanches and Fl{\'a}via de Lima Os{\'o}rio and Rafael Guimar{\~a}es dos Santos and Ligia Ribeiro Horta de Macedo and Joao Paulo Maia-de-Oliveira and Lauro Wichert-Ana and Dr{\'a}ulio de Ara{\'u}jo and Jordi Riba and Jos{\'e} Alexandre S. Crippa and Jaime E.C. Hallak},
  journal={Journal of Clinical Psychopharmacology},
  year={2016},
  volume={36},
  pages={77–81}
}
Abstract Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open… Expand
Long-term effects of ayahuasca in patients with recurrent depression: a 5-year qualitative follow-up
TLDR
The results suggest that ayahuasca was well tolerated and that symptom reductions were limited to a few weeks, and most patients believed that the experience was among the most important of their lives, even 4-7 years later. Expand
Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies
TLDR
Considering the need for new drugs that produce fewer adverse effects and are more effective in reducing anxiety and depression symptomatology, the described effects of ayahuasca and its alkaloids should be further investigated. Expand
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomised placebo-controlled trial
TLDR
Robust evidence of rapid antidepressant effects of a single dosing session with ayahuasca when compared to placebo is observed, providing new evidence ofRapid antidepressant effects for treatment-resistant major depression. Expand
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
TLDR
New evidence is brought new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression, in the first controlled trial to test a psychedelic substance in treatment-resistant depression. Expand
The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging
TLDR
Acute, subacute, and long-term AYA use seems to have low toxicity, and preliminary studies about potential therapeutic effects of AYA need replication due to their methodological limitations. Expand
Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans
TLDR
A systematic literature review using the PubMed database found five animal studies and five observational studies of regular ayahuasca consumers that showed improvement of biochemical or behavioral parameters related to drug-induced disorders. Expand
Ayahuasca - potential therapeutic properties in psychiatry. Research review.
TLDR
The complex profile of action and the resulting potential benefits, but also the risk of interaction and adverse effects associated with the taking of ayahuasca are explained, which is important given the high variability of herbal mixtures used to produce the decoction. Expand
Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities
TLDR
The present findings support the claim that ayahuasca has therapeutic potential and suggest that this potential is due to an increase in mindfulness capacities. Expand
Anti-inflammatory activity of ayahuasca: therapeutical implications in neurological and psychiatric diseases
TLDR
It is suggested, based on the available evidence, that ayahuasca is a promising and very safe therapeutic strategy since extremely high doses are required to reach toxicity, however, additional studies are needed to confirm such evidence. Expand
Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016–2020) systematic review of preclinical and human studies
TLDR
The findings of the previous review suggesting that ayahuasca and its alkaloids have therapeutic effects in the treatment of SUDs are replicated, however, translation of preclinical data to humans is limited, observational studies do not allow us to infer causality, and there is a lack of standardization onAyahuasca doses. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report.
OBJECTIVES Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore haveExpand
Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies
TLDR
Considering the need for new drugs that produce fewer adverse effects and are more effective in reducing anxiety and depression symptomatology, the described effects of ayahuasca and its alkaloids should be further investigated. Expand
Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics
TLDR
Drug administration increased urinary normetanephrine excretion, but, contrary to the typical MAO-inhibitor effect profile, deaminated monoamine metabolite levels were not decreased, suggesting a predominantly peripheral (gastrointestinal and liver) site of action for harmine. Expand
Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
TLDR
The present results suggest that ayahuasca interacts with neural systems that are central to interoception and emotional processing and point to a modulatory role of serotonergic neurotransmission in these processes. Expand
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
TLDR
This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety. Expand
Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report
TLDR
There is lack of specificity in the diagnosis of substance-induced mental disorder and the knowledge of the pharmacodynamic properties of ayahuasca consumption allows a more physiopathological approach to the diagnoses of the patient. Expand
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca.
TLDR
An ethnopharmacological overview of the major tryptamine-containing New World hallucinogens and a model in which ayahuasca reduces top-down constraints and facilitates bottom-up information transfer are proposed, which temporarily disrupts neural hierarchies allowing inner exploration and a new outlook on reality. Expand
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
TLDR
In addition to marked hallucinogenic effects, LSD exerts methylenedioxymethamphetamine-like empathogenic mood effects that may be useful in psychotherapy, supporting the use of LSD in translational psychiatric research. Expand
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
TLDR
Results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted. Expand
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects
TLDR
Cannabidiol significantly augmented the activating effects of ketamine, as measured by the activation subscales of the BPRS, however, CBD showed a non-significant trend to reduce ketamine-induced depersonalization, as measures by the CADSS. Expand
...
1
2
3
4
...